Because the multidose vials of meningococcal and influenza vaccines currently available for pediatric use contain 25 [micro]g EtHg per 0.
These effects were found only at doses of 200-3,000 [micro]g EtHg/kg/BW, which is 15-500 times the level of EtHg found in pediatric vaccines.
In the present study, animals in the TCV group demonstrated increased response latencies in learning-set testing compared with the control group but this was not found in animals in the 1990s Primate group, which received the same EtHg exposure.
In the present study we examined neurobehavioral effects of TCVs using both an accelerated vaccine primate schedule and the recommended pediatric schedule, neither of which appeared to affect neurobehavioral outcomes, thus suggesting that the toxicokinetics of EtHg in infant primates is not a limiting factor when using an accelerated schedule of dosing.
For example, higher exposure to EtHg through vaccination in boys was associated with poorer behavioral regulation and a higher likelihood of motor tics, whereas girls performed significantly better in tests of visual-motor coordination when tested at 7-10 years of age (Thompson et al.